The biotech firm joins a group of health care companies advancing their IPO plans. Maze Theraupeutics Inc., which develops precision treatments for kidney, heart and metabolic diseases ...

The future of the Bay Area biotech firm Allakos was riding on one clinical trial, for a drug designed to treat the skin condition known as chronic spontaneous urticaria, or chronic hives.

Side effects of biologic drugs may include: respiratory infections headaches flu-like symptoms swelling, itching, or a rash at the injection site urinary tract infection Two types of biologic ...

But a small number of people do have problems. The most common problem you might have is a flare-up of your arthritis just after your injection. This might cause more pain and swelling in the ...

China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at $17.25 ...

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

How will the Trump administration approach healthcare regulation? Will generalist investors remain wary of biotech? Can the industry’s expensive pivot into immunology and obesity deliver drugs ...

Ascentage sold 7,325,000 American Depositary shares at $17.25 each. Credit: Andrey Zhuravlev via Getty Images. China-based biotech Ascentage Pharma has raised $126m in a US initial public offering ...